Cetirizine use in childhood: an update of a friendly 30-year drug

Cetirizine is a second-generation antihistamine, derived from the metabolism of hydroxyzine, highly specific for the H1 receptors, and with marked antiallergic properties. Although its history began more than 30 years ago, it remains one of the most used drugs in children with a leading role in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Giuseppe Fabio, Leonardi, Salvatore, Ciprandi, Giorgio, Corsico, Angelo, Licari, Amelia, Miraglia del Giudice, Michele, Peroni, Diego, Salpietro, Carmelo, Marseglia, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043022/
https://www.ncbi.nlm.nih.gov/pubmed/32127782
http://dx.doi.org/10.1186/s12948-020-00118-5
_version_ 1783501383981334528
author Parisi, Giuseppe Fabio
Leonardi, Salvatore
Ciprandi, Giorgio
Corsico, Angelo
Licari, Amelia
Miraglia del Giudice, Michele
Peroni, Diego
Salpietro, Carmelo
Marseglia, Gian Luigi
author_facet Parisi, Giuseppe Fabio
Leonardi, Salvatore
Ciprandi, Giorgio
Corsico, Angelo
Licari, Amelia
Miraglia del Giudice, Michele
Peroni, Diego
Salpietro, Carmelo
Marseglia, Gian Luigi
author_sort Parisi, Giuseppe Fabio
collection PubMed
description Cetirizine is a second-generation antihistamine, derived from the metabolism of hydroxyzine, highly specific for the H1 receptors, and with marked antiallergic properties. Although its history began more than 30 years ago, it remains one of the most used drugs in children with a leading role in the medical care of children with allergic diseases. Cetirizine use is licensed for paediatric patients for the treatment of allergic rhinitis, and chronic spontaneous urticaria, in Europe in children older than 2 years old and in the USA in children older than 6 months old. This review provides a practical update on the use of cetirizine in children and adolescents.
format Online
Article
Text
id pubmed-7043022
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70430222020-03-03 Cetirizine use in childhood: an update of a friendly 30-year drug Parisi, Giuseppe Fabio Leonardi, Salvatore Ciprandi, Giorgio Corsico, Angelo Licari, Amelia Miraglia del Giudice, Michele Peroni, Diego Salpietro, Carmelo Marseglia, Gian Luigi Clin Mol Allergy Review Cetirizine is a second-generation antihistamine, derived from the metabolism of hydroxyzine, highly specific for the H1 receptors, and with marked antiallergic properties. Although its history began more than 30 years ago, it remains one of the most used drugs in children with a leading role in the medical care of children with allergic diseases. Cetirizine use is licensed for paediatric patients for the treatment of allergic rhinitis, and chronic spontaneous urticaria, in Europe in children older than 2 years old and in the USA in children older than 6 months old. This review provides a practical update on the use of cetirizine in children and adolescents. BioMed Central 2020-02-26 /pmc/articles/PMC7043022/ /pubmed/32127782 http://dx.doi.org/10.1186/s12948-020-00118-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Parisi, Giuseppe Fabio
Leonardi, Salvatore
Ciprandi, Giorgio
Corsico, Angelo
Licari, Amelia
Miraglia del Giudice, Michele
Peroni, Diego
Salpietro, Carmelo
Marseglia, Gian Luigi
Cetirizine use in childhood: an update of a friendly 30-year drug
title Cetirizine use in childhood: an update of a friendly 30-year drug
title_full Cetirizine use in childhood: an update of a friendly 30-year drug
title_fullStr Cetirizine use in childhood: an update of a friendly 30-year drug
title_full_unstemmed Cetirizine use in childhood: an update of a friendly 30-year drug
title_short Cetirizine use in childhood: an update of a friendly 30-year drug
title_sort cetirizine use in childhood: an update of a friendly 30-year drug
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043022/
https://www.ncbi.nlm.nih.gov/pubmed/32127782
http://dx.doi.org/10.1186/s12948-020-00118-5
work_keys_str_mv AT parisigiuseppefabio cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT leonardisalvatore cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT ciprandigiorgio cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT corsicoangelo cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT licariamelia cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT miragliadelgiudicemichele cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT peronidiego cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT salpietrocarmelo cetirizineuseinchildhoodanupdateofafriendly30yeardrug
AT marsegliagianluigi cetirizineuseinchildhoodanupdateofafriendly30yeardrug

Ejemplares similares